help button home button Am J Pathol ASIP WHAT IS IT?
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ohgaki, H.
Right arrow Articles by Kleihues, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ohgaki, H.
Right arrow Articles by Kleihues, P.
(American Journal of Pathology. 2007;170:1445-1453.)
© 2007 American Society for Investigative Pathology
DOI: 10.2353/ajpath.2007.070011

Review

Genetic Pathways to Primary and Secondary Glioblastoma

Hiroko Ohgaki* and Paul Kleihues{dagger}

From the International Agency for Research on Cancer,* Lyon, France; and the Department of Pathology,{dagger} University of Zurich, Zurich, Switzerland

Abstract

Glioblastoma is the most frequent and most malignant human brain tumor. The prognosis remains very poor, with most patients dying within 1 year after diagnosis. Primary and secondary glioblastoma constitute distinct disease subtypes, affecting patients of different age and developing through different genetic pathways. The majority of cases (>90%) are primary glioblastomas that develop rapidly de novo, without clinical or histological evidence of a less malignant precursor lesion. They affect mainly the elderly and are genetically characterized by loss of heterozygosity 10q (70% of cases), EGFR amplification (36%), p16INK4a deletion (31%), and PTEN mutations (25%). Secondary glioblastomas develop through progression from low-grade diffuse astrocytoma or anaplastic astrocytoma and manifest in younger patients. In the pathway to secondary glioblastoma, TP53 mutations are the most frequent and earliest detectable genetic alteration, already present in 60% of precursor low-grade astrocytomas. The mutation pattern is characterized by frequent G:C->A:T mutations at CpG sites. During progression to glioblastoma, additional mutations accumulate, including loss of heterozygosity 10q25-qter (~70%), which is the most frequent genetic alteration in both primary and secondary glioblastomas. Primary and secondary glioblastomas also differ significantly in their pattern of promoter methylation and in expression profiles at RNA and protein levels. This has significant implications, particularly for the development of novel, targeted therapies, as discussed in this review.




This article has been cited by other articles:


Home page
 Ann OncolHome page
B. Neyns, J. Sadones, E. Joosens, F. Bouttens, L. Verbeke, J.-F. Baurain, L. D'Hondt, T. Strauven, C. Chaskis, P. In't Veld, et al.
Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma
Ann. Onc., June 2, 2009; (2009) mdp032v1.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
T. Watanabe, S. Nobusawa, P. Kleihues, and H. Ohgaki
IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas
Am. J. Pathol., April 1, 2009; 174(4): 1149 - 1153.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
Y. Zhu, A. Wloch, Q. Wu, C. Peters, A. Pagenstecher, H. Bertalanffy, and U. Sure
Involvement of PTEN Promoter Methylation in Cerebral Cavernous Malformations
Stroke, March 1, 2009; 40(3): 820 - 826.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
H. Yan, D. W. Parsons, G. Jin, R. McLendon, B. A. Rasheed, W. Yuan, I. Kos, I. Batinic-Haberle, S. Jones, G. J. Riggins, et al.
IDH1 and IDH2 Mutations in Gliomas
N. Engl. J. Med., February 19, 2009; 360(8): 765 - 773.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
V. Suri, P. Das, A. Jain, M. C. Sharma, S. A. Borkar, A. Suri, D. Gupta, and C. Sarkar
Pediatric glioblastomas: A histopathological and molecular genetic study
Neuro-oncol, January 1, 2009; 11(3): 274 - 280.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. B. Dinca, K. V. Lu, J. N. Sarkaria, R. O. Pieper, M. D. Prados, D. A. Haas-Kogan, S. R. VandenBerg, M. S. Berger, and C. D. James
p53 Small-Molecule Inhibitor Enhances Temozolomide Cytotoxic Activity against Intracranial Glioblastoma Xenografts
Cancer Res., December 15, 2008; 68(24): 10034 - 10039.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. C. Milsom, J. L. Yu, N. Mackman, J. Micallef, G. M. Anderson, A. Guha, and J. W. Rak
Tissue Factor Regulation by Epidermal Growth Factor Receptor and Epithelial-to-Mesenchymal Transitions: Effect on Tumor Initiation and Angiogenesis
Cancer Res., December 15, 2008; 68(24): 10068 - 10076.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. H. Garfield and A. Hercbergs
Fewer Dollars, More Sense
J. Clin. Oncol., November 10, 2008; 26(32): 5304 - 5305.
[Full Text] [PDF]

Home page
 Am. J. Neuroradiol.Home page
T. Kato, J. Shinoda, N. Oka, K. Miwa, N. Nakayama, H. Yano, T. Maruyama, Y. Muragaki, and T. Iwama
Analysis of 11C-methionine Uptake in Low-Grade Gliomas and Correlation with Proliferative Activity
AJNR Am. J. Neuroradiol., November 1, 2008; 29(10): 1867 - 1871.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
J.-H. Walzlein, M. Synowitz, B. Engels, D. S. Markovic, K. Gabrusiewicz, E. Nikolaev, K. Yoshikawa, B. Kaminska, G. Kempermann, W. Uckert, et al.
The Antitumorigenic Response of Neural Precursors Depends on Subventricular Proliferation and Age
Stem Cells, November 1, 2008; 26(11): 2945 - 2954.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
F. J. Attenello, D. Mukherjee, G. Datoo, M. J. McGirt, E. Bohan, J. D. Weingart, A. Olivi, A. Quinones-Hinojosa, and H. Brem
Use of Gliadel (BCNU) Wafer in the Surgical Treatment of Malignant Glioma: A 10-Year Institutional Experience
Ann. Surg. Oncol., October 1, 2008; 15(10): 2887 - 2893.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
L. W Buie and J. Valgus
Bevacizumab: A Treatment Option for Recurrent Glioblastoma Multiforme
Ann. Pharmacother., October 1, 2008; 42(10): 1486 - 1490.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
D. W. Parsons, S. Jones, X. Zhang, J. C.-H. Lin, R. J. Leary, P. Angenendt, P. Mankoo, H. Carter, I-M. Siu, G. L. Gallia, et al.
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Science, September 26, 2008; 321(5897): 1807 - 1812.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
P. Y. Wen and S. Kesari
Malignant Gliomas in Adults
N. Engl. J. Med., July 31, 2008; 359(5): 492 - 507.
[Full Text] [PDF]

Home page
 NeurologyHome page
W. P. Mason and J. G. Cairncross
Invited Article: The expanding impact of molecular biology on the diagnosis and treatment of gliomas
Neurology, July 29, 2008; 71(5): 365 - 373.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
F. G. Davis, B. S. Malmer, K. Aldape, J. S. Barnholtz-Sloan, M. L. Bondy, T. Brannstrom, J. M. Bruner, P. C. Burger, V. P. Collins, P. D. Inskip, et al.
Issues of Diagnostic Review in Brain Tumor Studies: From the Brain Tumor Epidemiology Consortium
Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 484 - 489.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. Yang, G. Wu, R. F. Barth, M. R. Swindall, A. K. Bandyopadhyaya, W. Tjarks, K. Tordoff, M. Moeschberger, T. J. Sferra, P. J. Binns, et al.
Molecular Targeting and Treatment of Composite EGFR and EGFRvIII-Positive Gliomas Using Boronated Monoclonal Antibodies
Clin. Cancer Res., February 1, 2008; 14(3): 883 - 891.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
S. C. Short, C. Martindale, S. Bourne, G. Brand, M. Woodcock, and P. Johnston
DNA repair after irradiation in glioma cells and normal human astrocytes
Neuro-oncol, October 1, 2007; 9(4): 404 - 411.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Society for Investigative Pathology.